Burgher Abram H, Barnett Crawford F, Obray Jon B, Mauck W David
Department of Anesthesiology, Division of Pain Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.
Pain Pract. 2007 Sep;7(3):279-84. doi: 10.1111/j.1533-2500.2007.00142.x.
Implantable pain therapy devices for chronic pain include spinal cord stimulators (SCS) and intrathecal drug delivery systems (IDDS). A number of different complications can occur after implantation of these devices, but among the most serious is infection. Based on Centers for Disease Control and Prevention guidelines for prevention of surgical site infection, published literature on infection risk with implantable pain therapy devices, and recommendations from groups within our own our institution, we introduced infection control measures for all patients receiving either SCS or IDDS.
After approval from the Institutional Review Board, we performed a retrospective review of patients undergoing primary implantation of SCS or IDDS before and after introduction at our institution of safety measures designed to reduce device-related infection. We compared infection incidence and compliance to infection precautions before and after introduction of these measures.
Thirty-four SCS or IDDS were implanted before implementation of the infection control measures and 58 were placed after. Five device-related infections occurred. Adherence to most infection precautions improved during the study period, but 100% compliance was seen only with venue used for implantation. Infection incidence declined after introduction of the safety measures, but the reduction was not statistically significant.
Introduction of infection control measures for implantable pain therapy devices improved adherence to most infection precautions in our practice. Lack of specific documentation could have hindered practice surveillance within our group. A tool to document performance of infection control measures would be useful not only as a marker of compliance but could also serve as a reminder to perform certain safety measures.
用于慢性疼痛的植入式疼痛治疗设备包括脊髓刺激器(SCS)和鞘内药物输送系统(IDDS)。植入这些设备后可能会出现多种不同的并发症,但其中最严重的是感染。根据疾病控制与预防中心关于预防手术部位感染的指南、已发表的关于植入式疼痛治疗设备感染风险的文献以及我们机构内部各小组的建议,我们为所有接受SCS或IDDS治疗的患者引入了感染控制措施。
在获得机构审查委员会批准后,我们对在我们机构引入旨在降低与设备相关感染的安全措施之前和之后接受SCS或IDDS初次植入的患者进行了回顾性研究。我们比较了这些措施引入前后的感染发生率以及对感染预防措施的遵守情况。
在实施感染控制措施之前植入了34个SCS或IDDS,之后植入了58个。发生了5起与设备相关的感染。在研究期间,对大多数感染预防措施的遵守情况有所改善,但仅在植入场所方面达到了100%的遵守率。引入安全措施后感染发生率有所下降,但降幅无统计学意义。
为植入式疼痛治疗设备引入感染控制措施提高了我们实践中对大多数感染预防措施的遵守程度。缺乏具体记录可能妨碍了我们小组内的实践监测。一种记录感染控制措施执行情况的工具不仅可作为遵守情况的标志,还可作为执行某些安全措施的提醒。